EVALUATION OF PLATINOL ANALOGS USING THE M5076 MURINE SARCOMA
- 1 July 1986
- journal article
- research article
- Vol. 6 (4) , 557-562
Abstract
The M5076 sarcoma was used to evaluate the antitumor activities of several analogs of Platinol presently undergoing clinical trials. The objective was to find a model yielding preclinical data which correlated with evolving clinical results, and thus potentially provide a validated model for the subsequent tesing of new Platinol analogs. The model found to be useful consisted of mice implanted s.c. with M5076 tumor fragments. Platinol, carboplatin, and iproplatin were consistently active (T/C values .gtoreq. 125%), whereas spiroplatin was consistently inactive. These findings reflect the clinical activities of Platinol, carboplatin, and iproplatin and the essential clinical inactivity of spiroplatin thus far reported.This publication has 8 references indexed in Scilit:
- CARBOPLATIN - A VERY ACTIVE NEW CISPLATIN ANALOG IN THE TREATMENT OF SMALL CELL LUNG-CANCER1985
- ACTIVITY OF JM9 IN ADVANCED OVARIAN-CANCER - A PHASE-I-II TRIAL1985
- Comparison of the antitumor activity of DTIC and 1-p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt on murine transplantable tumors and their hematological toxicityCancer Chemotherapy and Pharmacology, 1984
- The chemosensitivity of a new experimental model—the M5076 reticulum cell sarcomaEuropean Journal of Cancer and Clinical Oncology, 1984
- INHIBITED GROWTH OF A RETICULUM-CELL SARCOMA (M5076) INDUCED INVITRO AND INVIVO BY MACROPHAGE-ACTIVATING AGENTS1984
- OVARIAN RETICULAR CELL-SARCOMA OF THE MOUSE (M5076) MADE RESISTANT TO CYCLOPHOSPHAMIDE1983
- EXPERIMENTAL ANTI-TUMOR ACTIVITY AND TOXICITY OF A NEW CHEMOTHERAPEUTIC AGENT, BBM928A1983
- PHASE-II STUDY OF JM8, A NEW PLATINUM ANALOG, IN ADVANCED OVARIAN-CARCINOMA1983